Longwen Xu

510 total citations
24 papers, 361 citations indexed

About

Longwen Xu is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Longwen Xu has authored 24 papers receiving a total of 361 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 15 papers in Molecular Biology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Longwen Xu's work include Ferroptosis and cancer prognosis (7 papers), Melanoma and MAPK Pathways (5 papers) and Cutaneous Melanoma Detection and Management (5 papers). Longwen Xu is often cited by papers focused on Ferroptosis and cancer prognosis (7 papers), Melanoma and MAPK Pathways (5 papers) and Cutaneous Melanoma Detection and Management (5 papers). Longwen Xu collaborates with scholars based in China, Ethiopia and Taiwan. Longwen Xu's co-authors include Huan Yu, Jun Guo, Chuanliang Cui, Xiaowen Wu, Jie Dai, Tianxiao Xu, Junya Yan, Zhihong Chi, Yan Kong and Lu Si and has published in prestigious journals such as Journal of Clinical Oncology, Frontiers in Immunology and Journal of Pharmaceutical Sciences.

In The Last Decade

Longwen Xu

23 papers receiving 358 citations

Peers

Longwen Xu

ONCOL

IMMUN

PRM

Junya Yan China

Anxo Martínez-Ordóñez Spain

Loucia Kit Ying Chan Hong Kong

Mai Sugiyama Japan

Roberto Borea Italy

Suchitra Natarajan United States

Justin Wang United States

Tianxiao Xu China

Sara Vitale Italy

Antonio Agostini Norway

Junya Yan China

Longwen Xu

241 ×1.3

234 ×1.4

ONCOL

97 ×1.0

94 ×1.2

IMMUN

48 ×0.8

PRM

Citations per year, relative to Longwen Xu Longwen Xu (= 1×) peers Junya Yan

Countries citing papers authored by Longwen Xu

Since Specialization

Citations

This map shows the geographic impact of Longwen Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Longwen Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Longwen Xu more than expected).

Fields of papers citing papers by Longwen Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Longwen Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Longwen Xu. The network helps show where Longwen Xu may publish in the future.

Co-authorship network of co-authors of Longwen Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Longwen Xu. A scholar is included among the top collaborators of Longwen Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Longwen Xu. Longwen Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Xu, Longwen, et al.. (2025). Insights into interactions between taxanes and P-glycoprotein using biophysical and in silico methods. Journal of Pharmaceutical Sciences. 114(5). 103708–103708. 1 indexed citations

Zeng, Qingnuo, et al.. (2024). Platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with gastric cancer undergoing radical resection. Frontiers in Oncology. 14. 1279011–1279011. 5 indexed citations

Xu, Longwen, et al.. (2023). ncRNAs-mediated overexpression of STIL predict unfavorable prognosis and correlated with the efficacy of immunotherapy of hepatocellular carcinoma. Cancer Cell International. 23(1). 44–44. 5 indexed citations

Xu, Longwen, Mengjie Liu, Jie Lian, et al.. (2023). A prognostic nomogram for predicting recurrence-free survival of stage I–III colon cancer based on immune-infiltrating Treg-related genes. Journal of Cancer Research and Clinical Oncology. 149(15). 13523–13543.

Zeng, Qingnuo, et al.. (2023). Glucose metabolism‐based signature predicts prognosis and immunotherapy strategies for colon adenocarcinoma. The Journal of Gene Medicine. 26(1). e3620–e3620. 2 indexed citations

Zhang, Shirong, Longwen Xu, Jinteng Feng, et al.. (2022). ASF1B is a Promising Prognostic Biomarker and Correlates With Immunotherapy Efficacy in Hepatocellular Carcinoma. Frontiers in Genetics. 13. 842351–842351. 10 indexed citations

Jia, Xiaohui, Lili Jiang, Yanlin Li, et al.. (2022). Predicting checkpoint inhibitors pneumonitis in non-small cell lung cancer using a dynamic online hypertension nomogram. Lung Cancer. 170. 74–84. 13 indexed citations

Feng, Jinteng, Longwen Xu, Shirong Zhang, et al.. (2022). A robust CD8+ T cell-related classifier for predicting the prognosis and efficacy of immunotherapy in stage III lung adenocarcinoma. Frontiers in Immunology. 13. 993187–993187. 5 indexed citations

Li, Wenyuan, Shumei Wang, Lei Wang, et al.. (2022). Characteristics of the immunogenicity and tumor immune microenvironment in HER2-amplified lung adenocarcinoma. Frontiers in Immunology. 13. 1042072–1042072. 8 indexed citations

10.

Lin, Tao, Hao Cheng, Da Liu, et al.. (2021). A Novel Six Autophagy-Related Genes Signature Associated With Outcomes and Immune Microenvironment in Lower-Grade Glioma. Frontiers in Genetics. 12. 698284–698284. 12 indexed citations

11.

Yu, Jinyu, Longwen Xu, Junya Yan, et al.. (2020). MUC4 isoforms expression profiling and prognosis value in Chinese melanoma patients. Clinical and Experimental Medicine. 20(2). 299–311. 5 indexed citations

12.

Xu, Longwen, Zhiyuan Cheng, Chuanliang Cui, et al.. (2019). Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy. Journal of Translational Medicine. 17(1). 245–245. 27 indexed citations

13.

Yu, Jiayi, Xiaowen Wu, Junya Yan, et al.. (2019). Potential Mutations in Uveal Melanoma Identified Using Targeted Next-Generation Sequencing. Journal of Cancer. 10(2). 488–493. 7 indexed citations

14.

Tang, Huan, Meng Ma, Jie Dai, et al.. (2019). miR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy. Journal of Experimental & Clinical Cancer Research. 38(1). 212–212. 43 indexed citations

15.

Yan, Junya, Xiaowen Wu, Jiayi Yu, et al.. (2018). Establishment and characterization of melanoma patient-derived xenograft models for preclinical evaluation of novel therapeutics. Melanoma Research. 28(6). 527–535. 3 indexed citations

16.

Yu, Jiayi, Xiaowen Wu, Junya Yan, et al.. (2018). Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients. Journal of Hematology & Oncology. 11(1). 1–1. 140 indexed citations

17.

Yan, Junya, Jiayi Yu, Xiaowen Wu, et al.. (2018). Increased AURKA Gene Copy Number Correlates with Poor Prognosis and Predicts the Efficacy of High-dose Interferon Therapy in Acral Melanoma. Journal of Cancer. 9(7). 1267–1276. 9 indexed citations

18.

Yan, Junya, Longwen Xu, Jiayi Yu, et al.. (2018). Prognostic role of NRAS isoforms in Chinese melanoma patients. Melanoma Research. 29(3). 263–269. 4 indexed citations

19.

Yu, Huan, Meng Ma, Junya Yan, et al.. (2017). Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy. Journal of Translational Medicine. 15(1). 243–243. 19 indexed citations

20.

Li, Yize, Wei Xu, Qianrong Wang, et al.. (2016). Inhibition of miR-7 promotes angiogenesis in human umbilical vein endothelial cells by upregulating VEGF via KLF4. Oncology Reports. 36(3). 1569–1575. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact